版本:
中国

BRIEF-Antibe Therapeutics provides update on clinical development program for ATB-346

April 18 Antibe Therapeutics Inc

* Antibe Therapeutics provides update on clinical development program for its lead drug, ATB-346

* Antibe Therapeutics Inc - earlier initiation of key GI safety clinical trial, facilitating earlier strategic exit discussions

* Antibe Therapeutics Inc says GI study to be completed at approximately year-end and other phase 2 study to be concluded by end of Q2/18

* Antibe - first phase 2, double-blind, upper GI safety study will be active comparator trial versus naproxen, will be conducted in 240 healthy volunteers Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐